Clinical trials: Clopidogrel
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Aortic Valve Disorder
Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.
This is a prospective, randomized pilot study in patients undergoing Sugical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) to estimate the incidence of reduced leaflet motion and assess the…
- Trial name
- NCT02696226
- Testing
- SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Acute Coronary Syndrome
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
This is a multicenter, randomized, double-blind, cross-over study to compare the pharmacodynamic response in subjects with Acute Coronary Syndrome receiving a 10-mg maintenance dose (MD) of prasugrel compared with a 150-mg…
- Trial name
- NCT00385944
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease, Drug Interaction Potentiation
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
Previous reports have shown a possible drug interaction between clopidogrel and proton pump inhibitors (PPI´s), which could result in increased number of adverse cardiovascular events among patients on dual antiplatelet…
- Trial name
- NCT01896557
- Testing
- omeprazole, Ranitidine, Clopidogrel
- Volunteers
- 92 people
- Sponsor
- University of Sao Paulo General Hospital
HIV-1 Infection
Targeting Platelets in Chronic HIV Infection
Advances in antiretroviral therapy (ART) have resulted in increased survival of the HIV-infected population; however, this gain in longevity is associated with an increased risk of cardiovascular disease (CVD).
- Trial name
- NCT02578706
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Coronary Syndrome, Cardiovascular Diseases
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy.
- Trial name
- ADAPT (NCT02508116)
- Testing
- CYP2C19 genotyping
- Where
- 2 sites in United States
- Volunteers
- 509 people
- Sponsor
- University of Pennsylvania
Coronary Artery Disease
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.
- Trial name
- BOCLAplan (NCT01212302)
- Testing
- Optimizing ASA and clopidogrel treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ruhr University of Bochum
Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Trial name
- NCT01138969
- Testing
- esomeprazole
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
PRU(Platelet Reactivity Unit), APT(Antiplatelet Therapy)
Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
Since thrombus formation is a very complex procedure in vivo, platelet function testing methods in vitro might only reflect the degree of inhibition of platelet from a certain level, which do't reflect the functional status of…
- Conditions
- PRU(Platelet Reactivity Unit), APT(Antiplatelet Therapy), HOTPR(High on Treat Platelet Reactivity)
- Trial name
- NCT02101411
- Testing
- PRU(Platelet reactivity unit)
- Where
- Taiwan
- Volunteers
- 334 people
- Sponsor
- Taipei City Hospital
Stroke, Myocardial Infarctions
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications.
- Trial name
- NCT01586975
- Testing
- Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Northwestern University
Ischemic Stroke
POSITIVE Stroke Clinical Trial
Primary Endpoint: The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom…
- Trial name
- NCT01852201
- Testing
- Endovascular Mechanical Thrombectomy
- Where
- 20 sites in United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Breast Neoplasms
A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
- Trial name
- NCT00263211
- Testing
- Plavix, Aspirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company